Sangart Raises $50 Million

Sangart Inc., a San Diego-based developer of an artificial blood substitute, has raised $50 million in Series F funding led by return backer Leucadia National Corp. The deal also includes warrants which, if exercised, could provide another $50 million in funding. Sangart previously had raised more than $70 million in VC funding since its 1998 formation.